Safety, efficacy and impact on quality of life of long-term administration of Dilaudid CR [controlled release] (hydromorphone hydrochloride) in patients with chronic low back pain.
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2009
At a glance
- Drugs Hydromorphone (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors ALZA Corporation
- 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual end date (Jun 2001) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual patient number (207) added as reported by ClinicalTrials.gov.